Pituitary Macroadenoma Development in Transgender Women Receiving Gender-Affirming Hormone Therapy: A Call for Baseline Prolactin Screening Prior to Initiation of Therapy
AACE Endocrinology and Diabetes · 2026-10
DOI: 10.1016/j.aed.2026.09.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift AACE Endocrinology and Diabetes, 2026-10. Verfasst von Youssef Abdullah und 3 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Abdullah, Y., Naous, E., Torun, N., & Feldman, A. Z. (2026). Pituitary Macroadenoma Development in Transgender Women Receiving Gender-Affirming Hormone Therapy: A Call for Baseline Prolactin Screening Prior to Initiation of Therapy. AACE Endocrinology and Diabetes. https://doi.org/10.1016/j.aed.2026.09.025
Vancouver
Abdullah Y, Naous E, Torun N, Feldman AZ. Pituitary Macroadenoma Development in Transgender Women Receiving Gender-Affirming Hormone Therapy: A Call for Baseline Prolactin Screening Prior to Initiation of Therapy. AACE Endocrinology and Diabetes. 2026. doi:10.1016/j.aed.2026.09.025
BibTeX
@article{Abdullah2026,
author = {Abdullah, Youssef and Naous, Elie and Torun, Nurhan and Feldman, Anna Z.},
title = {Pituitary Macroadenoma Development in Transgender Women Receiving Gender-Affirming Hormone Therapy: A Call for Baseline Prolactin Screening Prior to Initiation of Therapy},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
doi = {10.1016/j.aed.2026.09.025}
}
EUVIMED